Search Results 2381-2390 of 23996 for Periods

  1. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

    ... period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF - Platelets > 600 ...

  2. Examining Alaska Native peoples' perspectives about options for colorectal cancer screening - Mayo Clinic

    ... period," explains Dr. Kisiel. "Surprisingly, the majority of people who chose colonoscopy and agreed to postscreening survey participation indicated that ...

  3. Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer - Mayo Clinic

    About this study. This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of ...

  4. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

    ... period as well as after registration while awaiting insurance approval for the use of palbociclib. Measurable disease as defined by RECIST criteria or bone ...

  5. Publications - Omar M. Ghanem, M.D. - Mayo Clinic

    ... period. Surg Endosc. 2025 Jan; 39 (1):180-183 Epub 2024 Oct 29. View PubMed; Kumar SS, Wunker C, Collings A, Bansal V, Zoumpou T, Chang J, Rodriguez N, Sabour ...

  6. low testosterone Archives - Mayo Clinic News Network

    ends and hormone production plummets during a relatively short period of time. In men, production of testosterone and other hormones declines over a period of ...

  7. Publications - Elird Bojaxhi, M.D. - Mayo Clinic

    Reduced Pain and Opioid Use in the Early Postoperative Period in Patients Undergoing a Frontotemporal Craniotomy under Regional vs General Anesthesia. World ...

  8. Efficacy and Safety of Intranasal MSP-2017 for the Conversion of PSVT to Sinus Rhythm (NODE-1) - Mayo Clinic

    ... period within 28 days of the Treatment Visit. Exclusion Criteria: Has a history of sensitivity to verapamil; Is currently participating in another drug or ...

  9. Altered microglial function with augmented neuritogenic factor by maternal immune activation - Molecular Neurotherapeutics - Mayo Clinic Research

    Maternal immune activation disrupts the central innate immune system during a critical neurodevelopmental period. Microglia are primary innate immune cells ...

  10. Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2) - Mayo Clinic

    ... period between Visit 1 and Visit 2. Have a documented history of P. aeruginosa infection. Are clinically stable and have not required a change in pulmonary ...